|
Guide |
|
Abstract
|
Received: 12 March 2020
|
|
Fund: |
|
|
|
[1] |
刘海玲, 范磊, 李建勇. Castleman 病的诊疗进展. 中华 血液学杂志, 2020, 41(8): 697-700.DOI: 10.3760/cma. j.issn.0253-2727.2020.08.017.
|
[2] |
刘秀芬, 马静, 周丽娟,等. Castleman病最新研究进展.中国医 学文摘(耳鼻咽喉科学), 2019, 34(5): 360-363. DOI: 10.19617/ j.issn1001-1307.2019.05.360.
|
[3] |
Wu D, Lim M S, Jaffe E S. Pathology of Castleman Disease. Hematol Oncol Clin North Am, 2018,32(1): 37-52. DOI:10.1016/j.hoc.2017.09.004.
|
[4] |
石梦晗, 刘婉莹, 余莉. Castleman病的临床病理特征及 可能的发病机制. 中国肿瘤临床, 2020, 47(13): 677-681. DOI:10.3969/j.issn.1000-8179.2020.13.599.
|
[5] |
江新利, 苗慧鹏, 周忠友, 等. 眼眶浆细胞型Castleman病一例 . 中华眼视光学与视觉科学杂志, 2014, 16(4): 251-252. DOI: 10.3760/cma.j.issn.1674-845X.2014.04.014.
|
[6] |
Mukherjee B, Alam M S, Krishnakumar S. A rare case of bilateral orbital Castleman disease. Orbit, 2014, 33(4): 314-317. DOI: 10.3109/01676830.2014.904381.
|
[7] |
包婕, 王希明, 胡粟, 等. 眼眶内Castleman 病一例. 中 华放射学杂志, 2018, 52(1): 61-62. DOI: 10.3760/cma. j.issn.1005?1201.2018.01.013.
|
[8] |
Kurokawa T, Suzuki S, Kawaguchi K, et al. Castleman disease presenting with ophthalmic signs and symptoms. Am J Ophthalmol, 1999, 128(1): 114-116. DOI: 10.1016/s0002- 9394(99)00027-6.
|
[9] |
Venizelos I, Papathomas T G, Papathanasiou M, et al. Orbital Involvement in Castleman Disease.Surv Ophthalmol, 2010, 55(3): 247-255. DOI: 10.1016/j.survophthal.2009.09.003.
|
[10] |
Sato Y , Kojima M, Takata K, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease. Mod Pathol, 2009, 22(4): 589- 599. DOI: 10.1038/modpathol.2009.17.
|
[11] |
秦晓怡, 林锦镛, 杨顺海. IgG4相关性眼病的病理诊断研究进 展. 中华眼视光学与视觉科学杂志, 2020, 22(2): 94-97. DOI: 10.3760/cma.j.issn.1674-845X. 2020.02.003.
|
[12] |
焦洋, 张文, 黄晓明, 等. IgG4 相关疾病误诊为多中心型 Castleman病3例并文献回顾. 中华临床免疫和变态反应杂志, 2013, 7(2): 154-159. DOI: 10.3969/j.issn.1673-8705.2013.02.012.
|
[13] |
Sato Y, Kojima M , Takata K, et al. Multicentric Castleman's disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases. J Clin Pathol, 2010, 63(12): 1084-1089. DOI: 10.1136/jcp.2010.082958.
|
[14] |
Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg, 2012, 255(4): 677-684. DOI: 10.1097/SLA.0b013e318249dcdc.
|
[15] |
Van Rhee F, Casper C, Voorhees PM, et al. A phase 2, openlabel, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget, 2015, 6(30): 30408- 30419. DOI: 10.18632/oncotarget.4655.
|
[1] |
. [J]. Chinese Journal of Optometry Ophthalmology and Visual science, 2023, 25(8): 0-. |
|
|
|